HMB002
Phase 2Biologic
HMB002 is one of 15 biologic programs targeting Acute Liver Failure. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Acute Liver Failure
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Medrol
PfizerPhase 2
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Benadryl
PParkedale
Phase 2
Equine Anti-Thymocyte Globulin
NNational Cancer Institute (NCI)
Phase 2
Plasma Exchange
SanofiPreclinical
Granulocyte Colony-Stimulating Factor
SanofiPreclinical
HMB002
KKing's College Hospital NHS Trust
Phase 2
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HMB002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details